// Script to change toggle default state //G Smith second script to show/hide Leadership sections
Press Releases  |  August 2, 2024

>

NeOnc Technologies Receives California Investment Forum’s Breakthrough Medical Technology Achievement Award
NeOnc has been honored with the California Investment Forum’s Breakthrough Medical Technology Achievement Award. This prestigious recognition underscores the company’s cutting-edge approach to brain cancer treatment.

NeOnc Technologies Receives California Investment Forum’s Breakthrough Medical Technology Achievement Award

Publication Date: August 2, 2024
Published By: The Cancer Letter
Article  Link: https://cancerletter.com/in-brief/20240802_7f/

NeOnc Technologies Holdings Inc., a clinical-stage biopharmaceutical company, has received the Breakthrough Medical Technology Achievement Award from the California Investment Forum for its innovations in medical technology related to the treatment
of brain and central nervous system diseases.

The award was presented to NeOnc by California State Treasurer, Fiona Ma, at the 2024 CIF Innovation Awards ceremony held last Friday in Anaheim, California. The 2024 CIF Innovation Awards recognizes “groundbreaking companies for leading the charge towards an innovative future.”

California State Treasurer Fiona Ma

NeOnc was selected from among the several leading companies from around the world and across multiple sectors who participated in the annual investment forum held last week. The California Investment Forum provides companies with direct access to a network of investors and partners dedicated to fostering innovative solutions.

“The award helps to bring important attention to our NEO drug development platform which has the potential to elevate the standard of care for primary brain tumors and other cancers that can spread to the brain,” Thomas Chen, NeOnc founder, CEO, and chief science officer, said at the ceremony.

Secured under exclusive worldwide rights from the University of Southern California, NeOnc’s intellectual property portfolio includes 135 U.S. and international issued and pending patents